SNPに対するジーンチップによる肺癌EGFR変異遺伝子関連遺伝子の発見とその解析

利用SNP基因芯片发现和分析肺癌EGFR突变基因相关基因

• 批准号: 19590924
• 负责人: マエモンド マコト
• 金额: $ 2.91万
• 依托单位: Miyagi Cancer Center Research Institute
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2007
• 资助国家: 日本
• 起止时间: 2007 至 2008
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-19590924/
• 关键词: 非閉塞性肺疾患癌; 肺線維症; 呼吸器感染症; その他・肺癌; EGFR遺伝子変異; 癌; 遺伝子

Lung cancer is a major cause of cancer death, and one of the most resistant cancers to treatment. Several mutations in the lung tumor were found so far, which were studied in terms of the association with oncogenicity, targets of therapy. It was demonstrated that epidermal growth factor receptor (EGFR) mutation in tumor cells exists among the lung cancer patients but not among other organ type of cancer. Gefitinib is an orally administered tyrosine kinase inhibitor (TKI) of EGFR that was approved in Japan for the first time in the world. This drug has substantial role on treatment with non-small cell lung cancer patients, especially has characteristics that include female, never smoker, and adenocarcinoma histology. The response of treatment with gefitinib was found strongly correlated with both these patients characteristics and EGFR mutations. In addition, it was reported that there are more EGFR mutations in tumor cells of Asians than in Westerners. On the hypotheses of that there are associate genes with this ethnic difference in incidence of mutation in the tumor cells, we conducted the study to identify these associated genes by the analysis of SNP through the whole genome with Gene chip assay.

肺癌是癌症死亡的主要原因，也是对治疗最具抗性的癌症之一。迄今为止，在肺肿瘤中发现了几种突变，这些突变与致瘤性、治疗靶点的相关性进行了研究。研究表明，肺癌患者肿瘤细胞中存在表皮生长因子受体（EGFR）突变，而其他器官类型的肿瘤细胞中不存在EGFR突变。吉非替尼是一种EGFR的口服酪氨酸激酶抑制剂（TKI），在日本获批，这在全球尚属首次。该药物对非小细胞肺癌患者的治疗具有重要作用，特别是具有女性，从不吸烟和腺癌组织学特征的患者。吉非替尼治疗的反应与这些患者的特征和EGFR突变密切相关。此外，据报道，亚洲人的肿瘤细胞中EGFR突变比西方人更多。基于肿瘤细胞中存在与这种突变发生率种族差异相关的基因的假设，我们进行了本研究，通过基因芯片技术对整个基因组进行SNP分析，以鉴定这些相关基因。

项目成果

Suppression of surfactant protein A by an epidermal growth factor receptor tyrosine kinase inhibitor exacerbates lung inflammation

• DOI: 10.1111/j.1349-7006.2008.00857.x
• 发表时间: 2008-08-01
• 期刊: CANCER SCIENCE
• 影响因子: 5.7
• 作者: Inoue, Akira;Xin, Hong;Saijo, Yasuo
• 通讯作者: Saijo, Yasuo

Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells

• DOI: 10.1038/sj.cgt.7701079
• 发表时间: 2007-11-01
• 期刊: CANCER GENE THERAPY
• 影响因子: 6.4
• 作者: Kanehira, M.;Xin, H.;Saijo, Y.
• 通讯作者: Saijo, Y.

Randomized phase 11 trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer : North japan lung Cancer : Study Group Trial 0402

比较氨柔比星与拓扑替康在既往治疗过的小细胞肺癌患者中的随机 11 期试验：北日本肺癌：研究组试验 0402

• 发表时间: 2008
• 期刊: J Clin Oncol 26
• 作者: Inoue A;Sugawara S;Yamazaki
• 通讯作者: Yamazaki

Rendomized phase 11 trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer : North japan lung Cancer Study Group Trial 0402

随机化 11 期试验比较氨柔比星与拓扑替康对既往接受过治疗的小细胞肺癌患者的治疗效果：北日本肺癌研究组试验 0402

• 发表时间: 2008
• 期刊: J Clin Oncol 26(33)
• 作者: Inoue A;Sugawara S;Yamazaki k
• 通讯作者: Yamazaki k